Sun Pharmaceutical Industries Ltd. has launched Ilumya (Tildrakizumab) in India for the treatment of moderate-to-severe plaque psoriasis. This novel biologic treatment has shown significant and long-lasting skin clearance. A clinical study in India showed a 75% skin clearance in 62.3%, 83.3% and 93.9% of patients at Weeks 12, 16, and 28, respectively. Ilumya is well-tolerated, offering a safe and effective option for patients.
Ilumya for Psoriasis Treatment
Sun Pharma has introduced Ilumya (Tildrakizumab) in India. It is a novel biologic treatment option for moderate-to-severe plaque psoriasis.
Clinical Study Results
A clinical study conducted in India with 115 patients showed promising results. At weeks 12, 16, and 28, 75% skin clearance was observed in 62.3%, 83.3%, and 93.9% of patients, respectively. Additionally, 90% skin clearance was seen in 26.3%, 50%, and 78.1% of patients at weeks 12, 16, and 28, respectively. The study involved three subcutaneous injections of Tildrakizumab over 16 weeks, followed by a 28-week observation period.
Dermatologist Perspective
According to Dr. B. S. Chandrashekar, Ilumya has demonstrated significant improvements across all measures, with approximately 93.5% reduction in PASI score and pronounced skin clearance. This is expected to improve the quality of life for psoriasis patients.
Long-Term Efficacy
Ilumya is the first IL-23 inhibitor to complete five years of study. Data shows that Ilumya is a sustainable choice for patients needing long-term therapy.
Source: BSE